The introduction of the Jak2 inhibitor AG490 blocked IL-6/Jak2 signaling, resulting in the amelioration of the poststroke neurological deficit, brain infarction, brain edema, oxidative stress, pro-inflammatory cytokine expression, and caspase-3 activation. The gene discussed is IL6; the disease is brain infarction.